Bonus BioGroup (OTCPK:BBIX.F) - Stock Price, News & Analysis

BBIX.F Stock Overview

A clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy.

BBIX.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 5% per year over past 5 years

Makes less than USD$1m in revenue (₪0)

Shares are highly illiquid

+ 1 more risk

Bonus BioGroup Ltd. Competitors

NextCure

NasdaqGS:NXTC

US$38.3m

Protara Therapeutics

NasdaqGM:TARA

US$39.4m

Lantern Pharma

NasdaqCM:LTRN

US$37.0m

Equillium

NasdaqCM:EQ

US$40.0m

Price History & Performance

Summary of all time highs, changes and price drops for Bonus BioGroup
Historical stock prices
Current Share Price	₪0.025
52 Week High	₪0.055
52 Week Low	₪0.0003
Beta	1.02
11 Month Change	-28.57%
3 Month Change	-37.50%
1 Year Change	n/a
33 Year Change	-93.24%
5 Year Change	n/a
Change since IPO	-80.56%

Recent updates

Shareholder Returns

	BBIX.F	US Biotechs	US Market
7D	0%	0.6%	0.8%
1Y	n/a	27.4%	38.4%

Return vs Industry: Insufficient data to determine how BBIX.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how BBIX.F performed against the US Market.

Price Volatility

Is BBIX.F's price volatile compared to industry and market?
BBIX.F volatility
BBIX.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: BBIX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BBIX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	58	Shai Meretzki	bonus-bio.com

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts.

Bonus BioGroup Ltd. Fundamentals Summary

How do Bonus BioGroup's earnings and revenue compare to its market cap?
BBIX.F fundamental statistics
Market cap	US$38.31m
Earnings (TTM)	-US$7.85m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.9x

P/E Ratio

Is BBIX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BBIX.F income statement (TTM)
Revenue	₪0
Cost of Revenue	₪0
Gross Profit	₪0
Other Expenses	₪29.19m
Earnings	-₪29.19m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.025
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did BBIX.F perform over the long term?

See historical performance and comparison

Bonus BioGroup OTCPK:BBIX.F Stock Report